Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol. 2010;72(3):377–82.
Asa SL, Ezzat S. The pathogenesis of pituitary tumors. Annu Rev Pathol. 2009;4:97–126.
Fontana E, Gaillard R. Epidemiology of pituitary adenoma: results of the first Swiss study. Rev Med Suisse. 2009;5(223):2172–4.
Dhandapani S, Singh H, Negm HM, Cohen S, Anand VK, Schwartz TH. Cavernous sinus invasion in pituitary adenomas: systematic review and pooled data meta-analysis of radiologic criteria and comparison of endoscopic and microscopic surgery. World Neurosurg. 2016;96:36–46.
Dai C, Feng M, Liu X, et al. Refractory pituitary adenoma: a novel classification for pituitary tumors. Oncotarget. 2016;7(50):83657–68.
Micko AS, Wohrer A, Wolfsberger S, Knosp E. Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg. 2015;122(4):803–11.
Mooney MA, Hardesty DA, Sheehy JP, et al. Interrater and intrarater reliability of the Knosp scale for pituitary adenoma grading. J Neurosurg. 2017;126:1714–9.
Juraschka K, Khan OH, Godoy BL, et al. Endoscopic endonasal transsphenoidal approach to large and giant pituitary adenomas: institutional experience and predictors of extent of resection. J Neurosurg. 2014;121(1):75–83.
Bao X, Deng K, Liu X, et al. Extended transsphenoidal approach for pituitary adenomas invading the cavernous sinus using multiple complementary techniques. Pituitary. 2016;19(1):1–10.
Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006;6(3):227–39.
Wieczorek E, Jablonska E, Wasowicz W, Reszka E. Matrix metalloproteinases and genetic mouse models in cancer research: a mini-review. Tumour Biol. 2015;36(1):163–75.
Kawamoto H, Kawamoto K, Mizoue T, Uozumi T, Arita K, Kurisu K. Matrix metalloproteinase-9 secretion by human pituitary adenomas detected by cell immunoblot analysis. Acta Neurochir. 1996;138(12):1442–8.
Kawamoto H, Uozumi T, Kawamoto K, Arita K, Yano T, Hirohata T. Type IV collagenase activity and cavernous sinus invasion in human pituitary adenomas. Acta Neurochir. 1996;138(4):390–5.
Peker S, Kurtkaya-Yapicier O, Kilic T, Pamir MN. Microsurgical anatomy of the lateral walls of the pituitary fossa. Acta Neurochir. 2005;147(6):641–8. discussion 649
Knappe UJ, Fink T, Fisseler-Eckhoff A, Schoenmayr R. Expression of extracellular matrix-proteins in perisellar connective tissue and dura mater. Acta Neurochir. 2010;152(2):345–53. discussion 353
Ceylan S, Anik I, Koc K, et al. Microsurgical anatomy of membranous layers of the pituitary gland and the expression of extracellular matrix collagenous proteins. Acta Neurochir. 2011;153(12):2435–43. discussion 2443
Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A. 1990;87(14):5578–82.
Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE. Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a “cysteine switch” mechanism for activation. Proc Natl Acad Sci U S A. 1990;87(1):364–8.
Liu W, Kunishio K, Matsumoto Y, Okada M, Nagao S. Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas. J Clin Neurosci. 2005;12(7):791–4.
Liu W, Matsumoto Y, Okada M, et al. Matrix metalloproteinase 2 and 9 expression correlated with cavernous sinus invasion of pituitary adenomas. J Med Invest. 2005;52(3–4):151–8.
Gurlek A, Karavitaki N, Ansorge O, Wass JA. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol. 2007;156(2):143–53.
Jugenburg M, Kovacs K, Stefaneanu L, Scheithauer BW. Vasculature in Nontumorous Hypophyses, pituitary adenomas, and carcinomas: a quantitative morphologic study. Endocr Pathol. 1995;6(2):115–24.
Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wass JA. Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome. J Endocrinol. 2000;165(2):475–81.
Turner HE, Nagy Z, Esiri MM, Harris AL, Wass JA. Role of matrix metalloproteinase 9 in pituitary tumor behavior. J Clin Endocrinol Metab. 2000;85(8):2931–5.
Pan LX, Chen ZP, Liu YS, Zhao JH. Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space. J Neuro-Oncol. 2005;74(1):71–6.
Wang J, Voellger B, Benzel J, et al. Metalloproteinases ADAM12 and MMP-14 are associated with cavernous sinus invasion in pituitary adenomas. Int J Cancer. 2016;139(6):1327–39.
Hui P, Xu X, Xu L, Hui G, Wu S, Lan Q. Expression of MMP14 in invasive pituitary adenomas: relationship to invasion and angiogenesis. Int J Clin Exp Pathol. 2015;8(4):3556–67.
Wu TT, Hsieh YH, Hsieh YS, Liu JY. Reduction of PKC alpha decreases cell proliferation, migration, and invasion of human malignant hepatocellular carcinoma. J Cell Biochem. 2008;103(1):9–20.
Noh EM, Park YJ, Kim JM, et al. Fisetin regulates TPA-induced breast cell invasion by suppressing matrix metalloproteinase-9 activation via the PKC/ROS/MAPK pathways. Eur J Pharmacol. 2015;764:79–86.
Lin CW, Shen SC, Chien CC, Yang LY, Shia LT, Chen YC. 12-O-tetradecanoylphorbol-13-acetate-induced invasion/migration of glioblastoma cells through activating PKCalpha/ERK/NF-kappaB-dependent MMP-9 expression. J Cell Physiol. 2010;225(2):472–81.
Lai KC, Huang AC, Hsu SC, et al. Benzyl isothiocyanate (BITC) inhibits migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloproteinase-2/−9 and urokinase plasminogen (uPA) through PKC and MAPK signaling pathway. J Agric Food Chem. 2010;58(5):2935–42.
Halder K, Banerjee S, Ghosh S, et al. Mycobacterium Indicus pranii (mw) inhibits invasion by reducing matrix metalloproteinase (MMP-9) via AKT/ERK-1/2 and PKCalpha signalling: a potential candidate in melanoma cancer therapy. Cancer Biol Ther. 2015;18:850–62.
Chandrika G, Natesh K, Ranade D, Chugh A, Shastry P. Suppression of the invasive potential of Glioblastoma cells by mTOR inhibitors involves modulation of NFkappaB and PKC-alpha signaling. Sci Rep. 2016;6:22455.
Akter H, Park M, Kwon OS, Song EJ, Park WS, Kang MJ. Activation of matrix metalloproteinase-9 (MMP-9) by neurotensin promotes cell invasion and migration through ERK pathway in gastric cancer. Tumour Biol. 2015;36(8):6053–62.
Alvaro V, Touraine P, Raisman Vozari R, Bai-Grenier F, Birman P, Joubert D. Protein kinase C activity and expression in normal and adenomatous human pituitaries. Int J Cancer. 1992;50(5):724–30.
Couldwell WT, Law RE, Hinton DR, Gopalakrishna R, Yong VW, Weiss MH. Protein kinase C and growth regulation of pituitary adenomas. Acta Neurochir Suppl. 1996;65:22–6.
Zhu Y, Dong Q, Tan BJ, Lim WG, Zhou S, Duan W. The PKCalpha-D294G mutant found in pituitary and thyroid tumors fails to transduce extracellular signals. Cancer Res. 2005;65(11):4520–4.
Alvaro V, Levy L, Dubray C, et al. Invasive human pituitary tumors express a point-mutated alpha-protein kinase-C. J Clin Endocrinol Metab. 1993;77(5):1125–9.
Hussaini IM, Trotter C, Zhao Y, et al. Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line. Am J Pathol. 2007;170(1):356–65.
Vogel W, Gish GD, Alves F, Pawson T. The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell. 1997;1(1):13–23.
Yoshida D, Teramoto A. Enhancement of pituitary adenoma cell invasion and adhesion is mediated by discoidin domain receptor-1. J Neuro-Oncol. 2007;82(1):29–40.
Li S, Zhang Z, Xue J, Guo X, Liang S, Liu A. Effect of hypoxia on DDR1 expression in pituitary adenomas. Med Sci Monit. 2015;21:2433–8.
Fabre J, Giustiniani J, Garbar C, et al. Targeting the tumor microenvironment: the Protumor effects of IL-17 related to cancer type. Int J Mol Sci. 2016;17(9):1433.
Qiu L, He D, Fan X, et al. The expression of interleukin (IL)-17 and IL-17 receptor and MMP-9 in human pituitary adenomas. Pituitary. 2011;14(3):266–75.
Knappe UJ, Hagel C, Lisboa BW, Wilczak W, Ludecke DK, Saeger W. Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue. Acta Neuropathol. 2003;106(5):471–8.
Feng J, Yu SY, Li CZ, Li ZY, Zhang YZ. Integrative proteomics and transcriptomics revealed that activation of the IL-6R/JAK2/STAT3/MMP9 signaling pathway is correlated with invasion of pituitary null cell adenomas. Mol Cell Endocrinol. 2016;436:195–203.
Moh MC, Lee LH, Yang X, Shen S. HEPN1, a novel gene that is frequently down-regulated in hepatocellular carcinoma, suppresses cell growth and induces apoptosis in HepG2 cells. J Hepatol. 2003;39(4):580–6.
Hu S, Tao R, Wang S, et al. MicroRNA-21 promotes cell proliferation in human hepatocellular carcinoma partly by targeting HEPN1. Tumour Biol. 2015;36(7):5467–72.
Peng H, Fan J, Wu J, et al. Silencing of HEPN1 is responsible for the aggressive biological behavior of pituitary somatotroph adenomas. Cell Physiol Biochem. 2013;31(2–3):379–88.
Amaral FC, Torres N, Saggioro F, et al. MicroRNAs differentially expressed in ACTH-secreting pituitary tumors. J Clin Endocrinol Metab. 2009;94(1):320–3.
Chambers TJ, Giles A, Brabant G, Davis JR. Wnt signalling in pituitary development and tumorigenesis. Endocr Relat Cancer. 2013;20(3):R101–11.
Li W, Zhang Y, Zhang M, Huang G, Zhang Q. Wnt4 is overexpressed in human pituitary adenomas and is associated with tumor invasion. J Clin Neurosci. 2014;21(1):137–41.
Zhao C, Zhang M, Liu W, Wang C, Zhang Q, Li W. Beta-catenin knockdown inhibits pituitary adenoma cell proliferation and invasion via interfering with AKT and gelatinases expression. Int J Oncol. 2015;46(4):1643–50.
Sun B, Liu X, Yang Y, et al. The clinical utility of TIMP3 expression in ACTH-secreting pituitary tumor. J Mol Neurosci. 2016;58(1):137–44.
Gultekin GD, Cabuk B, Vural C, Ceylan S. Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-2: prognostic biological markers in invasive prolactinomas. J Clin Neurosci. 2015;22(8):1282–7.
Eljarmak D, Lis M, Cantin M, Carriere PD, Collu R. Effects of chronic bromocriptine treatment of an estrone-induced, prolactin-secreting rat pituitary adenoma. Horm Res. 1985;21(3):160–7.
de Bruin C, Meij BP, Kooistra HS, Hanson JM, Lamberts SW, Hofland LJ. Cushing's disease in dogs and humans. Horm Res. 2009;71(Suppl 1):140–3.
Otto CA, Marshall JC, Lloyd RV, et al. Use of DES-treated rats as an animal model for assessment of pituitary adenoma imaging agents. Int J Rad Appl Instrum B. 1986;13(5):539–47.
Takekoshi S, Yasui Y, Inomoto C, Kitatani K, Nakamura N, Osamura RY. A Histopathological study of multi-hormone producing proliferative lesions in estrogen-induced rat pituitary Prolactinoma. Acta Histochem Cytochem. 2014;47(4):155–64.
Gong J, Zhao Y, Abdel-Fattah R, et al. Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas. Pituitary. 2008;11(1):37–48.
Tomita T. Matrix Metalloproteinases and tissue inhibitors of Metalloproteinases in pituitary adenomas: possible markers of Neuroendocrine cells. Endocr Pathol. 1997;8(4):305–13.
Liu HY, Gu WJ, Wang CZ, Ji XJ, Mu YM. Matrix metalloproteinase-9 and -2 and tissue inhibitor of matrix metalloproteinase-2 in invasive pituitary adenomas: a systematic review and meta-analysis of case-control trials. Medicine. 2016;95(24):e3904.